nPhase, Inc.
About nPhase, Inc.
nPhase, Inc. is a clinical research technology company that commercializes Vanderbilt-developed REDCap technology. It offers an AI-native clinical data platform that connects clinical trial and real-world data for pharmaceutical sponsors and life sciences organizations. The flagship nPhase.ai platform integrates data from sites, labs, patients, and sensors while providing AI agents for discrepancy flagging and statistical programming support. Headquartered in Atlantic Beach, Florida, the company focuses on modernizing clinical data management and workflows.
- ๐ Company commercializing Vanderbilt-developed REDCap technology raises $30 million | Center for Technology Transfer and Commercialization | Vanderbilt University
- ๐ nPhase raises $30M for clinical data platform
- ๐ nPhase Secures $30 Million in Series D Funding to Drive Global Expansion of AI-Native Clinical Data Platform for Life Sciences | Drug Discovery News
- ๐ nPhase Secures $30 Million to Expand AI-Powered Clinical Data Management Platform
- ๐ CS GROUP - 2026 Funding Rounds & List of Investors - Tracxn
Investors
Key highlights
- Raised $30M Series D led by Viking Global Investors in November 2026.
- First equity financing since 2017 to expand AI-native clinical data platform.
- Commercializes Vanderbilt REDCap technology for sponsors and academic researchers.
- Platform integrates trial, real-world, and sensor data with agentic AI tools.
- Headquartered in Atlantic Beach, Florida.
Ask StreetZero about nPhase, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Technology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account